LIFECORE BIOMEDICAL, INC. DE(LFCR)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

LIFECORE BIOMEDICAL, INC. DE (LFCR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LFCR at 29.7/100 on a 32-signal composite quality model, placing it at rank #2,520 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (12.9) and balance sheet strength (13.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 19.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), LIFECORE BIOMEDICAL, INC. DE reports quarterly revenue of $34.2M, net income of $-6.2M, free cash flow of $880.0K. Top institutional holders of LFCR by reported 13-F value include WYNNEFIELD CAPITAL, Legion Partners Asset Management, Greenhaven Road Investment Management, L.P., based on the most recent SEC filings. LFCR trades on the Nasdaq exchange and files with the SEC under CIK 1005286. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LFCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LIFECORE BIOMEDICAL, INC. DE directly from SEC EDGAR.